NYSE$IEX
IDEX Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
IDEX reported mixed results for Q1 2024, with sales declining but EPS exceeding expectations. The company confirmed its full-year guidance.
IDEX Corporation reported first-quarter sales of $801 million, a 5% decrease overall and a 6% organic decline, aligning with expectations. Despite the sales decrease, the company's adjusted diluted EPS of $1.88 exceeded expectations. Strong operating cash flow of $157 million, up 6%, and free cash flow of $137 million, up 13%, were also reported. The company confirmed its full-year guidance.
- Sales were $801 million, down 5% overall and 6% organically, in line with expectations.
- Reported diluted EPS was $1.60, down 13%, while adjusted diluted EPS was $1.88, down 10%, exceeding expectations.
- Operating cash flow was strong at $157 million, up 6%, and free cash flow was $137 million, up 13%.
- Full-year organic sales growth is projected to be 0% to 2% over the prior year, with GAAP diluted EPS of $7.13 - $7.43 (adjusted diluted EPS of $8.15 - $8.45).
Headline financials
Revenue & EPS history
IDEX · Revenue · Quarterly
$801M
Revenue by segment
IDEX · $795M total across 3 segments · Q3 2023
- Health & Science Technologies$313M-9.2%39.4%
- Fluid & Metering Technologies$301M-2.1%37.9%
- Fire & Safety/Diversified Products$181M+4.8%22.7%
Forward guidance
IDEX projects full year organic sales growth to be 0% to 2% over the prior year and second quarter organic sales are projected to decline 2% to 3% over the prior year period. Full year GAAP diluted EPS of $7.13 - $7.43 (adjusted diluted EPS of $8.15 - $8.45) and Second quarter GAAP diluted EPS of $1.75 - $1.80 (adjusted diluted EPS of $2.00 - $2.05).
Tailwinds
- Full year organic sales growth is projected to be 0% to 2% over the prior year
- Full year GAAP diluted EPS of $7.13 - $7.43
- Full year adjusted diluted EPS of $8.15 - $8.45
- Second quarter GAAP diluted EPS of $1.75 - $1.80
- Second quarter adjusted diluted EPS of $2.00 - $2.05
Headwinds
- Second quarter organic sales are projected to decline 2% to 3% over the prior year period
- Sales of $801 million, down 5% overall and 6% organically
- Reported diluted EPS of $1.60, down 13%
- Adjusted diluted EPS of $1.88, down 10%
- Organic net sales were down 6% primarily driven by lower volumes in our Health & Science Technologies segment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+8.4%
Q2 2018
Best reaction
-9.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +4.4% | +2.8% | |
| Q4 2025 | +5.3% | +4.5% | -1.8% | |
| Q3 2025 | +3.8% | +0.8% | +4.2% | |
| Q1 2025 | +0.7% | +3.2% | +4.0% | |
| Q4 2024 | -9.6% | -10.2% | -14.2% | |
| Q3 2024 | +6.7% | +5.5% | +12.8% | |
| Q2 2024 | -5.7% | -7.6% | -0.8% | |
| Q1 2024 | -2.3% | -4.0% | -6.2% | |
| Q4 2023 | +1.9% | +4.6% | +9.4% | |
| Q3 2023 | +0.2% | -1.1% | +3.4% | |
| Q2 2023 | +4.0% | +7.3% | +7.4% | |
| Q1 2023 | -3.5% | -4.0% | -5.5% | |
| Q4 2022 | -2.3% | -1.4% | -3.7% | |
| Q3 2022 | +6.1% | +7.6% | +13.7% | |
| Q2 2022 | +3.6% | +8.2% | +10.7% | |
| Q1 2022 | +0.2% | -1.0% | -1.4% | |
| Q4 2021 | -4.1% | -8.3% | -9.7% | |
| Q3 2021 | +0.5% | +0.6% | +6.7% | |
| Q2 2021 | -2.9% | +0.2% | -0.1% | |
| Q1 2021 | -0.2% | -0.6% | -1.6% | |
| Q4 2020 | -2.2% | +2.4% | +2.1% | |
| Q3 2020 | -9.2% | -10.4% | +0.8% | |
| Q2 2020 | -1.0% | -2.3% | +5.6% | |
| Q1 2020 | +0.7% | +4.0% | -0.8% | |
| Q4 2019 | -3.1% | -3.6% | -13.6% | |
| Q3 2019 | -2.0% | -0.2% | +2.5% | |
| Q2 2019 | +1.3% | +1.9% | -3.7% | |
| Q1 2019 | -0.1% | -0.0% | -2.4% | |
| Q4 2018 | +1.1% | +1.8% | +6.2% | |
| Q3 2018 | -4.8% | -4.6% | -0.4% | |
| Q2 2018 | +8.4% | +9.1% | +9.8% | |
| Q1 2018 | -2.1% | +0.0% | +1.0% | |
| Q4 2017 | +1.4% | -0.2% | -4.0% | |
| Q3 2017 | -0.3% | +1.0% | +1.5% | |
| Q2 2017 | +2.8% | +2.4% | -0.2% | |
| Q1 2017 | +7.1% | +9.2% | +14.1% | |
| Q4 2016 | -2.5% | -1.6% | +3.9% | |
| Q3 2016 | +0.4% | -0.1% | +6.9% | |
| Q2 2016 | +2.3% | +2.4% | +9.0% | |
| Q1 2016 | +0.8% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | -0.1% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | +0.7% | — | — | |
| Q4 2014 | -0.1% | — | — | |
| Q3 2014 | +4.8% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | +1.7% | — | — | |
| Q4 2013 | +4.3% | — | — | |
| Q3 2013 | +0.7% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q4 2012 | -2.9% | — | — | |
| Q3 2012 | +2.0% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2012 | -0.0% | — | — | |
| Q4 2010 | -0.8% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q3 2011 | -4.8% | — | — | |
| Q2 2011 | -3.9% | — | — | |
| Q1 2010 | -3.0% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q4 2008 | +3.7% | — | — | |
| Q3 2010 | +2.3% | — | — | |
| Q3 2009 | +2.3% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q2 2009 | +0.3% | — | — | |
| Q4 2009 | +0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro